Kyle LaHucik

An­oth­er obe­si­ty biotech emerged on Tues­day morn­ing, this time tak­ing a dif­fer­ent ap­proach to the GIP an­tag­o­nism sto­ry than Am­gen and an­oth­er start­up called An­tag

Met­sera, a well-fund­ed biotech try­ing to an­gle to­ward the front of the obe­si­ty med­i­cine pack, has pro­posed a $250 mil­lion IPO. That would be the

Maze Ther­a­peu­tics is eye­ing a $113 mil­lion ini­tial pub­lic of­fer­ing a lit­tle un­der two months af­ter re­veal­ing a $115 mil­lion Se­ries D. The clin­i­cal-stage biotech

Sion­na Ther­a­peu­tics and Odyssey Ther­a­peu­tics have joined Met­sera and Maze in an at­tempt to go pub­lic via the still rocky IPO route. The biotechs, fo­cused

The Chi­na-to-US ex­per­i­men­tal med­i­cine pipeline is bal­loon­ing: yet an­oth­er US-based biotech formed around a can­di­date from Chi­na’s Keymed Bio­sciences on Mon­day. Life sci­ences in­vest­ment firm

SAN FRAN­CIS­CO — Ben Aus­pitz, a vet­er­an biotech in­vestor and re­peat en­tre­pre­neur, is re­unit­ing with long­time col­lab­o­ra­tor Alex­is Borisy and his “free the founders” …